Ticker

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 502,390 shares, a growth of 2,578.7% from the March 31st total of 18,755 shares. Approximately 11.4% of the company's shares are short sold.

Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleinopathies and other CNS diseases. Among CNS unmet conditions, brain metastasis (BM) remains a lethal progression of the primary cancer in urgent need of novel and effective therapies.

Galmed said it developed a new formulation of its SCD1 inhibitor, Aramchol, designed to cross the blood-brain barrier and target central nervous system diseases.

98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary formulation of Aramchol which targets the brain.

TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the 'SEC').